Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 10, 2026
Why Is N-able, Inc. (NABL) Stock Down -35.27% Today?

Why Is N-able, Inc. (NABL) Stock Down -35.27% Today?

Key Takeaways

  • N-able, Inc. (NABL) shares plunged approximately 35.27% in Monday trading, falling from a prior close of $4.99 to around $3.23.
  • The sell-off was triggered by the company's Q2 2026 earnings report, which revealed sharply lower forward revenue guidance that fell well short of Wall Street consensus estimates.
  • N-able issued Q3 revenue guidance of $134.5 million to $135.5 million and full-year 2026 revenue guidance of $539 million to $542 million, both materially below analyst expectations.
  • Broader concerns around slowing IT spending among small and medium-sized businesses and intensifying competition in the cybersecurity software space compounded the negative reaction.
  • The stock had already declined roughly 37% over the prior six months, reflecting persistent investor skepticism about the company's growth trajectory.
  • Traders are now watching for potential analyst downgrades and whether the stock can stabilize at newly established support levels.

Opening Summary

NABL shares cratered on Monday, tumbling roughly 35.27% to approximately $3.23 after closing the previous trading session at $4.99 on August 7. N-able, Inc., a Burlington, Massachusetts-based provider of cloud-based software solutions for managed service providers (MSPs), reported its second-quarter 2026 financial results before the market opened. While Q2 revenue and non-GAAP earnings were roughly in line with analyst projections, it was the company's sharply reduced forward guidance that sent investors rushing for the exits. The stock was already down over 21% in pre-market trading before accelerating its losses once the regular session began.

Q2 Earnings Miss the Mark on Guidance

N-able reported second-quarter revenue of $138.2 million, representing a 5.9% year-over-year increase. Non-GAAP earnings per share came in at $0.10, matching consensus estimates. Subscription revenue grew 6.1% to $137.1 million, and adjusted EBITDA reached $39.9 million, representing a healthy margin of 28.9%. On a GAAP basis, net income was just $1.8 million, or $0.01 per diluted share, reflecting the company's razor-thin profitability. While these headline numbers were not catastrophic, the market's focus was firmly on what came next.

Forward Guidance Sparks Panic Selling

The central catalyst behind Monday's collapse was the company's outlook. N-able guided third-quarter 2026 revenue to a range of $134.5 million to $135.5 million, a figure that fell considerably short of the analyst consensus estimate of approximately $141.2 million. More critically, full-year 2026 revenue was forecast at $539 million to $542 million, compared to Wall Street's expectation of roughly $556 million. The company also updated its full-year 2026 annual recurring revenue (ARR) outlook to $562 million to $565 million, signaling only modest growth ahead. For a stock that had been priced for a recovery narrative, this guidance reset was devastating—confirming that N-able's growth engine is decelerating faster than the Street had anticipated.

Broader Concerns About Competitive and Spending Headwinds

Beyond the numbers, investors are grappling with deepening worries about N-able's competitive positioning. The company operates in an increasingly crowded cybersecurity and IT management software space, where larger players with deeper resources are exerting pricing pressure. Concerns about the defensibility of software solutions targeting small and medium-sized business customers have persisted for quarters. Additionally, macroeconomic uncertainty has prompted many enterprises to scrutinize IT budgets, potentially elongating sales cycles and slowing adoption of new products. These structural headwinds were echoed by institutional investor Conestoga Capital Advisors, which exited its entire NABL position in Q2 2026, citing a desire to concentrate software exposure in businesses with "stronger long-term growth and return potential."

Market Context and Trading Activity

The magnitude of Monday's sell-off placed NABL among the session's most severe decliners. Trading volume surged far above the daily average, reflecting a rush of institutional and retail selling as the market digested the guidance shortfall. The move was company-specific, diverging sharply from the broader technology sector and major indices, which traded in a more orderly fashion. From a technical standpoint, the stock sliced through multiple support levels, including its recent consolidation range near $4.70–$5.20. The prior 52-week low of $2.92 now looms as a potential downside reference point, while the stock's 50-day and 200-day moving averages sit far above current levels, offering little near-term technical support.

What Comes Next for NABL

Investors will now closely monitor whether Wall Street analysts adjust their ratings and price targets in the wake of the guidance reduction. Several firms, including Needham and BMO Capital, had already lowered price targets earlier in 2026, and further downward revisions appear likely. The upcoming earnings conference call and management's commentary on product pipeline traction—particularly around AI-powered cybersecurity tools and the company's move upmarket into larger MSP deals—will be critical in shaping sentiment. Key risks include potential customer churn, the delayed revenue contribution from new product launches, and the company's elevated debt load of approximately $392 million against $115.8 million in cash. On a more positive note, N-able's gross margin remains strong at over 76% on a GAAP basis, and the appointment of a new chief revenue officer in July signals an effort to revitalize the sales organization.

Trending AI Robots

In volatile market environments like the one impacting NABL today, traders increasingly turn to AI-driven trading tools to navigate sharp price swings. Tickeron's Trending AI Robots page showcases a curated selection of hundreds of AI trading bots that cover thousands of tickers across multiple strategies and timeframes. Only the strongest-performing bots under current market conditions are featured, allowing users to explore automated trading approaches that vary by strategy type, performance metrics, and traded symbols. For those seeking data-driven decision support amidst rapidly changing markets, exploring the Trending AI Robots section may offer valuable perspective.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NABL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


NABL's Stochastic Oscillator remains in overbought zone for 4 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NABL moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NABL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on NABL as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NABL just turned positive on August 03, 2026. Looking at past instances where NABL's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

NABL moved above its 50-day moving average on July 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NABL crossed bullishly above the 50-day moving average on July 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NABL advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

NABL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 125 cases where NABL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NABL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.177) is normal, around the industry mean (7.266). NABL's P/E Ratio (770.000) is considerably higher than the industry average of (71.568). NABL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.199). NABL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (1.777) is also within normal values, averaging (146.459).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NABL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 9.28B. The market cap for tickers in the group ranges from 0 to 223.55B. IBM holds the highest valuation in this group at 223.55B. The lowest valued company is ARSC at 0.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 52%. CACI experienced the highest price growth at 29%, while CYCU experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was -29%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 65
Price Growth Rating: 58
SMR Rating: 72
Profit Risk Rating: 93
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
NABL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry InformationTechnologyServices

Profile
Details
Industry
N/A
Address
30 Corporate Drive
Phone
+1 781 328-6490
Employees
1584
Web
https://www.n-able.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.